biostudies-literatureUnknown5(9)Zhou CF. Hoffmann-La RocheF. Hoffmann-La Roche Ltd<h4>Introduction</h4>Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced <i>ALK</i>-positive NSCLC, consistent with the global ALEX study. We present updated data after more than or equal to 5 years of follow-up from the "last patient in" date.<h4>Methods</h4>Adult patients with treatment-naïve, advanced <i>ALK</i>-positive NSCLC from mainland China, South Korea, and Thailand were randomized 2:1 to receive twice-daily 600 mg alectinib (n = 125) or 250 mg crizotinib (n = 62). The primary endpoint was investigator-assessed progression-free survival. Secondary or exploratory endpoints included overall survival, objective response rate, tJTO clinical and research reports100700https://www.ebi.ac.uk/biostudies/studies/S-EPMC11399573biostudies-literatureAlectinib Versus Crizotinib in Asian Patients With Treatment-Naive Advanced <i>ALK</i>-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.PMC11399573Kim SWBu LZhou MFang JHe JLu YLee SHZhang LCheng YHilton MYang JJLiu ZArcher VZhou CZhang YXu TReungwetwattana TChang JQian LZhou JfalseAlectinib Versus Crizotinib in Asian Patients With Treatment-Naive Advanced <i>ALK</i>-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.<h4>Introduction</h4>Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced <i>ALK</i>-positive NSCLC, consistent with the global ALEX study. We present updated data after more than or equal to 5 years of follow-up from the "last patient in" date.<h4>Methods</h4>Adult patients with treatment-naïve, advanced <i>ALK</i>-positive NSCLC from mainland China, South Korea, and Thailand were randomized 2:1 to receive twice-daily 600 mg alectinib (n = 125) or 250 mg crizotinib (n = 62). The primary endpoint was investigator-assessed progression-free survival. Secondary or exploratory endpoints included overall survival, objective response rate, t2024-01-01T00:00:00Z2024 Sep2025-04-04T11:34:00.718Z2025-04-04T11:34:00.718ZS-EPMC113995733928266310.1016/j.jtocrr.2024.100700